Skip to main
ACST
ACST logo

Acasti Pharma (ACST) Market Capitalization Overview

Market Cap: $38.96M as of Jun 13, 2025

$38.96M
Past Month+$1.65M (4.41%)
As of Jun 13, 2025, Acasti Pharma (ACST) has a market capitalization of $38.96M. Over the past 30 days, its market cap has increased by 3.69%, while in the last 12 months, it has increased by 2.73%.

Market capitalization represents the total value of Acasti Pharma as perceived by the stock market. It is calculated by multiplying the current stock price by the total number of outstanding shares.

Acasti Pharma (ACST) Market Cap Formula = Stock Price * Shares Outstanding

The market cap of Acasti Pharma (ACST) helps investors assess the company's size and compare it with competitors for better investment decisions.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Acasti Pharma (ACST) Market Cap History

DateMarket CapChange
Jun 2, 2025$38.55M+3.69%
May 1, 2025$37.18M+19.91%
Apr 1, 2025$31.01M-12.80%
Mar 3, 2025$35.56M+8.89%
Feb 3, 2025$32.66M-19.50%
Jan 2, 2025$40.56M+21.21%

Acasti Pharma (ACST) End of Year Market Cap History

DateMarket CapChange
2025$38.96M+2.73%
2024$37.93M

FAQs About Acasti Pharma (ACST) Market Cap

As of Jun 13, 2025, the market capitalization of Acasti Pharma (ACST) is $38.96M. Market cap represents the total value of a company’s outstanding shares and is a key indicator of its size in the stock market.

In the last 30 days, Acasti Pharma’s market capitalization has increased by 4.41%, changing from $37.32M to $38.96M as of Jun 13, 2025.

In the last 3 months, Acasti Pharma’s market capitalization has increased by —, changing from – to – as of –.

In the year 2024, Acasti Pharma’s market capitalization increased from – in January to $37.93M in December, reflecting a — change.

Acasti Pharma (ACST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.